TempraMed Technologies Ltd. News Releases

TempraMed Announces Additional Granted Brazilian Patent for Newest VIVI Box Product

Tue, 07 Apr 2026 07:00:00 -0400

Grant in Brazil marks a major milestone in global IP strategy, advancing protection of its VIVI Box across key international markets HighlightsBrazilian patent officially granted by the Brazilian Patent Office Covers core innovations underpinning TempraMed's VIVI Box™ multi-medication storage platform expected to market end of 2026Strengthens the Company's intellectual property position in one of the world's largest healthcare and consumer marketsSupports commercialization strategy and strategic...

TempraMed Signs LOI for Distribution Agreement in Panama, Expanding Central American Exposure

Mon, 30 Mar 2026 07:00:00 -0400

Vancouver, British Columbia--(Newsfile Corp. - March 30, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce that it has signed a non-binding letter of intent ("LOI"), dated March 22, 2026, with TEM Consulting International S.A. ("TEM") a leading healthcare logistics and consultancy company based in the Panama, with respect to the...

TempraMed Strengthens Global Intellectual Property Position with Granted Chinese Patent for Newest Product, VIVI Box

Tue, 24 Mar 2026 07:00:00 -0400

Grant in China marks a major milestone in global IP strategy, advancing protection of its VIVI Box platform across key international markets HighlightsChinese patent officially granted by CNIPA on March 17, 2026Covers core innovations underpinning TempraMed's VIVI Box™ multi-medication storage platform expected to market end of 2026Strengthens the Company's intellectual property position in one of the world's largest healthcare and consumer marketsSupports commercialization strategy and...

TempraMed's Independently Validated Payer ROI Model for Reimbursement Further Reinforced by a Scientific Publication Highlighting Clinical and Economic Rationale for VIVI Cap

Wed, 11 Mar 2026 07:00:00 -0400

Peer-reviewed case report by Prof. Andreas Pfützner demonstrates real-world insulin protection during extreme heat exposure and aligns with previously validated savings model Vancouver, British Columbia--(Newsfile Corp. - March 11, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, today announced the publication of a clinical case report evaluating...

TempraMed Reports over 275 Clinicians Recommending VIVI Cap to Patients on Leading FrontrowMD Platform Across the United States

Thu, 26 Feb 2026 07:00:00 -0500

Partnership results in over 275 physicians recommending VIVI Cap to patients, strengthening clinical validation and driving scalable patient education and acquisition Vancouver, British Columbia--(Newsfile Corp. - February 26, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce that more than 275 physicians across the United...

TempraMed Partners with Super-Pharm, Israel's Leading Pharmacy Chain to Commence a National Product Roll Out Strategy

Tue, 10 Feb 2026 03:00:00 -0500

Super-Pharm operates nationwide, serving millions of consumers annually Vancouver, British Columbia--(Newsfile Corp. - February 10, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is excited to announce the rollout of its products across Super-Pharm, Israel's largest and most prominent pharmacy and health-retail chain, operating nationwide and...

TempraMed Launches National Brick and Mortar Pharmacy Roll Out, Shipping Products to Maccabi Pharmacies Across Israel

Fri, 06 Feb 2026 03:00:00 -0500

Key Commercialization Milestone in Retail Pharmacy Network that Serves Over 2.8 Million Insured Members Vancouver, British Columbia--(Newsfile Corp. - February 6, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is excited to announce that it has completed initial sales of VIVI Cap, VIVI Cap Smart, VIVI Epi, and VIVI Med to pharmacies operated by...

TempraMed Enters Strategic Media Partnership with Dr. Phil's Envoy Media, Validating Product Portfolio and Accelerating Market Adoption Across the United States

Mon, 02 Feb 2026 03:00:00 -0500

Access to an audience of over 19 million individuals monthly will expand national exposure, and supports scalable demand generation across B2C and B2B channels for TempraMed's full product portfolio Vancouver, British Columbia--(Newsfile Corp. - February 2, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is excited to announce that it has entered...

TempraMed Launches New Product "VIVI Med(TM)," Unlocking New Growth Opportunities in High-Value Biologics and Injectable Medications

Fri, 23 Jan 2026 16:05:00 -0500

Using same proprietary, patented technology, VIVI Med extends the product portfolio beyond injectable pens, opening access to broader patient populations, premium biologics, and institutional channels HighlightsUses same fully patented, thermal-protection technology across product portfolio with four products in market that keep room temperature medications at optimal temperatureDesigned for medications beyond standard insulin pens, including vials, biologics, GLP-1 therapies, alternative...

TempraMed Receives Positive Response on Payor Reimbursement Model Driving Significant Return on Investment for Medical Payor Coverage

Wed, 14 Jan 2026 02:00:00 -0500

Validation is expected to accelerate TempraMed's path to payor reimbursement for product portfolio HighlightsROI model validated for savings and metrics by Validation Institute, a leading authority in healthcare value and economic credibilityConfirms that payors covering VIVI Cap™ can achieve meaningful cost savings and return on investmentSupports TempraMed's planned payor pilot programs aimed at confirming savings and securing reimbursement coverageEstablishes a scalable, reimbursement-driven...